Inebilizumab-cdon (Uplizna)

Provider Order Form rev. 01/02/2024

PATIENT INFORMATION	Referral Sta	i tus: □ New R	eferral 🗆 Updated	d Order □ Order Renewal	
Patient Name:		DOB:	•	t Phone:	
Patient Address:			Patient Email:		
Allergies:		□ NKDA	Weight (lbs/kg):	Height (in/cm):	
Sex: □ M / □ F Date of Last I	nfusion: Next Due		Preferred Location		
-		Date.	Treferred Location		
DIAGNOSIS (Please provide II					
	disorder with AQP4 positive antib	odies:			
Other:	Description:				
THERAPY ADMINISTRATIO	IN & DOSING	DRF-MEDI	CATION ORDERS		
	☐ Induction: Administer Uplizna 300mg IV at week 0, followed by			Ominutes prior to infusion	
300mg IV at week 2		☑ Required Tylenol 650mg PO ☑ Required Solumedrol 125mg IV			
☐ Maintenance: Administer Upliz	·				
(beginning 6 months after first do	•	☑ Required Benadryl 25 mg- 50mg ☐ PO / ☐ IV ☐ Other:			
☑ Dilute in 250ml NS, do not shall	·				
☑ Monitor patient for 1 hour pos	t infusion for signs and symptoms				
of adverse reaction		NURSING			
☑ Infuse at progressive rate listed below over 90 mins:			☑ Hold infusion and notify provider for signs or symptoms of		
Elapse Time (minutes)	Infusion Rate (ml/hr)		active infection/Recent live vaccine or suspected pregnancy ☑ Provide nursing care per Nursing Procedure, including Hypersensitivity Reaction Management Protocol and post- procedure observation		
0-30mins	42ml/hr				
31-60mins	125ml/hr				
61-90mins	333ml/hr	procedure of	osci vation		
PROVIDER INFORMATION Preferred Contact Name:	Dro	Preferred Contact Email:			
Ordering Provider:			Provider NPI:		
Referring Practice Name:		Phone:		ax:	
Practice Address:		City:	State:	Zip Code:	
REQUIRED DOCUMENTATI	ON CHECKLIST (Additional doc	,	wired for processing	·	
Required Documentation: Paties treatment failures or contraindicting, Documentation of optic new symptomatic cerebral syndrome	ent demos, copy of front and back cations with Rituximab, Quantitat uritis, acute myelitis, area postrene, Rule out MS and history of relagits, TB test results, Aqp4 Antibodic	of primary and s ive serum immu na syndrome, aco ose, Lesions cour	secondary insurance, noglobulins and posi ute brainstem syndro	, 2 most recent OVN including itive serological test for AQP4-	
Provider Name (print)	Provider Signa	Provider Signature		Date	